MITRAL VALVE DISEASE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Mitral Valve Disease Market Size and Trends

Global mitral valve disease market is estimated to be valued at USD 2.80 Bn in 2024 and is expected to reach USD 5.12 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9% from 2024 to 2031.

Discover market dynamics shaping the industry: Request sample copy

Mitral valve disease refers to conditions that affect the mitral valve in the heart. This includes mitral regurgitation, mitral stenosis, and mitral valve prolapse. Increasing geriatric population is one of the key factors contributing to the market growth. The market is witnessing positive growth trends over the forecast period supported by factors such as rising incidence of rheumatic heart diseases and implementation of novel technologies in mitral valve repair and replacement surgeries.

Discover high revenue pocket segments and roadmap to it: Request sample copy

Insights By Treatment Type - Proven Clinical Efficacy Drives Mitral Valve Repair Adoption

In terms of treatment type, mitral valve repair segment is estimated to contribute the highest market share of 42.1% in 2024, owing to its demonstrated long term clinical benefits over replacement procedures. Mitral valve repair aims to restore the native valve anatomy and physiology through techniques like annuloplasty rings and leaflet repairs. Long term outcomes studies have shown repair to be associated with superior valve durability, left ventricular function preservation, and improved survival rates compared to replacement. 

Insights By Indication - Mitral Valve Regurgitation Represents the Bulk of Caseload

In terms of indication, mitral valve regurgitation segment is estimated to contribute the highest market share of 36.12% in 2024. Mitral regurgitation, wherein the mitral valve does not close properly and allows blood to flow backward into the left atrium, accounts for the majority of mitral valve disease burden worldwide. It can result from structural abnormalities like flail leaflets or chordal rupture, or functional causes such as dilated cardiomyopathy.

Insights By Device Type - Surgical Instruments Facilitate the Procedure

In terms of device type, surgical instruments segment is estimated to contribute the highest market share of 41.1% in 2024. Mitral valve procedures extensively rely on specialized equipment to effectively handle heart tissue, implement repair techniques, and ensure safety and precision. Surgical instruments enable critical tasks like tissue stabilization, exposure, leaflet grasping and suturing in mitral valve repair. Stapling and clipping systems facilitate annuloplasty ring placement.

Regional Insights

To learn more about this report, Request sample copy

Dominating Region- North America

North America is expected to dominate the mitral valve disease market with an estimated market share of 39.2% in 2024, due to factors such as high healthcare expenditure, strong presence of leading medical device companies, and supportive reimbursement structures in countries like the U.S.

Fastest-Growing Region- Asia Pacific

Asia Pacific region exhibits the fastest growth due to rising geriatric population, growing medical tourism, increasing healthcare expenditure, and expansions by major industry players looking to tap into the region's high potential.

Mitral Valve Disease Market Outlook for Key Countries

U.S.- Leading Market with Advanced Healthcare Infrastructure

The U.S. is the largest market for mitral valve disease due to high healthcare expenditure and advanced medical technology. In May 2024, according to the American Heart Association, approximately 2 million people in the U.S. suffer from mitral valve regurgitation, thus, boosting demand for treatment options. The advanced healthcare infrastructure supports a wide range of innovative treatments and technologies in cardiology, including mitral valve interventions.

Canada- Growing Adoption of Innovative Treatments

Canada's healthcare system is increasingly adopting advanced mitral valve treatments, with a reported 15% increase in mitral valve surgeries from 2022 to 2023, as per the Canadian Institute for Health Information. In February 2024, as per the Hospital Stays in Canada, 2022–2023 Report, there were 2.96 million acute inpatient hospitalizations in Canada during that period, increase from 2.88 million in 2021–2022. The most common inpatient surgeries included caesarean sections, knee replacements, and hip replacements.

China- Expanding Market with Increasing Healthcare Investments

China's mitral valve disease market is indeed expanding rapidly, driven by significant investments in healthcare infrastructure and increasing number of surgical procedures. In August 2023, according to National Library of Medicine, there has been a notable increase in the number of mitral valve surgeries performed in 2023, reflecting the government's commitment to enhancing cardiac care across the country.

India- India's Mitral Valve Disease Market Witnesses Significant Growth Due to Increased Healthcare Awareness

India is experiencing significant growth in the mitral valve disease market, driven by increased healthcare awareness, improved access to cardiac care, and a growing middle class seeking advanced medical treatments. In December 2022, the total number of surgical heart valve procedures performed in India was 30,896. The conventional mitral valve procedure was the most performed surgical heart valve procedure in 2022 in India.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Request sample copy

Top Strategies Followed by Global Mitral Valve Disease Market Players

Established Players- Leading companies in the mitral valve disease market heavily invest in research and development to drive innovation. For example, Abbott Laboratories allocates over 7% of its annual revenue to R&D with the goal of developing minimally invasive cardiac devices. Edwards Lifesciences also dedicates significant resources to unveiling novel tissue heart valves with superior hemodynamics.

Mid-Level Players- Some mid-tier companies focus on delivering quality solutions at affordable price points. For instance, Micro Interventional Devices develops percutaneous mitral repair technologies priced 20-30% lower than competitive options. LivaNova also aims to meet the needs of price-sensitive healthcare facilities and patients with its affordable Portico device for mitral regurgitation treatment.

Small-Scale Players- Honor, a small-scale player, has integrated AI-driven health monitoring systems into its hospice care model. In December 2023, they launched a new telemedicine tool that uses AI to predict patient health declines, enabling early intervention and improved care outcomes.

Emerging Startups in the Global Mitral Valve Disease Market

Innovative Technologies- Startups like Carillon, Inc. have developed advanced technologies for mitral valve disease, specifically for percutaneous treatment solutions. In October 2023, Carillon launched an innovative device designed to treat heart failure in patients with functional mitral regurgitation. This minimally invasive procedure uses smart sensors to provide real-time data to healthcare providers, allowing for better decision-making during surgery and reducing recovery times.

Market Contribution- Startups like VascuTech specialize in the treatment of rare mitral valve conditions. In June 2023, VascuTech launched a targeted therapy for patients with mitral valve prolapse, a rare condition that often goes undiagnosed. This move into niche markets allows the company to address unmet needs in a smaller but critical patient population.

Mitral Valve Disease Industry News

• In June 2024, Foldax, Inc., a leader in the development of innovative, polymer heart valves, announced positive 30-day results from a clinical study of its TRIA mitral surgical heart valve, featuring the novel LifePolymer material, conducted in India. The study involved 67 patients, primarily females aged 19 to 67 with rheumatic heart disease. At 30 days post-surgery, the TRIA valve demonstrated favorable safety and hemodynamic performance, with imaging showing no signs of calcification or leaflet deterioration. These findings suggest that the TRIA valve could offer a durable, non-animal tissue heart valve option that may not require long-term anticoagulation therapy
• In November 2021, Medtronic plc, a medical device company, shared early results from the Intrepid transcatheter mitral valve replacement (TMVR) system, designed for patients with severe, symptomatic mitral valve regurgitation (MR) using the transfemoral access route. Data from the first five patients enrolled in an Early Feasibility Study demonstrated 100% survival, no strokes, and only trace or no MR in all implanted patients at 30 days.
• In September 2021, Abbott, a global pharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval for its Epic Plus and Epic Plus Supra Stented Tissue Valves. These innovations, built on Abbott's Epic surgical valve platform, expand therapeutic options for individuals with aortic or mitral valve disease.
• In June 2021, CORCYM, the newly independent medical device company committed to offering the best solutions for structural heart disease, has officially announced the global launch of its operations.
• In January 2020, Abbott, a global pharmaceutical company, received CE Mark approval for its Tendyne Transcatheter Mitral Valve Implantation (TMVI) system, enabling its use in Europe for treating mitral regurgitation (MR) in patients requiring heart valve replacement

Key Takeaways from Analyst

• Global mitral valve disease market can witness growth significantly over the forecast period due to rising prevalence of rheumatic heart disease and degenerative mitral valve diseases. Mitral regurgitation accounts for majority of mitral valve diseases primarily attributed to valve prolapse or flail leaflets causing backflow of blood into the left atrium. North America currently dominates the market due to growing geriatric population susceptible to degenerative mitral valve diseases. Asia Pacific is expected to offer lucrative opportunities, owing to increasing healthcare expenditure and patient awareness.
• Transcatheter mitral valve repair using clips, bands or replacement valves has emerged as a minimally invasive alternative to surgical valve repair and replacement. Widespread adoption of these transcatheter mitral procedures is likely to stimulate market growth. However, high cost of these mitral valve devices remains a major barrier particularly in developing regions. Reimbursement uncertainties and lack of clinical evidence for long-term outcomes of new mitral therapies may also impede market revenues.

Market Report Scope

Market Dynamics

Market Driver - Advancements in minimally invasive surgical techniques

Technological advancements in the past decade have led to the development of minimally invasive mitral valve surgeries. Unlike traditional open-heart procedures requiring sternotomy, these surgeries involve small incisions between the ribs, using specialized tools and video-assisted guidance. For instance, in April 2024, Medtronic plc, a medical device industry, announced one-year results from the SMART study, revealing that the Medtronic Evolut TAVR, Transcatheter Aortic Valve Replacement platform is the most effective therapy for severe aortic stenosis in patients with a small annulus, predominantly women.

Market Challenge- High cost of mitral valve repair and replacement procedures

One of the major challenges faced by global mitral valve disease market includes high cost associated with mitral valve repair and replacement procedures. Mitral valve surgery, whether its repair or replacement, is a complex open-heart surgery that requires highly skilled cardiac surgeons and advanced medical infrastructure. This makes the procedures quite expensive, often costing over US$ 100,000 in developed markets like the U.S. The financial burden on patients necessitates some form of health insurance coverage in most cases.

Market Opportunity- Growing Demand for Innovative Mitral Valve Treatment Options

There has been growing demand for innovative mitral valve treatment options in the market. While surgical repair and replacement remain the standard of care, the invasiveness and high cost associated with open-heart surgery boosts the need for minimally invasive alternatives. As a result, percutaneous and transcatheter mitral valve repair and replacement technologies have emerged as promising opportunities. Devices such as clip-based mitral valve repair systems and transcatheter mitral valve implantation provide a less invasive option for high-risk or inoperable patients.

Key Stakeholders of Market

What does Global Mitral Valve Disease Market Mean for Different Stakeholders?

Global mitral valve disease market has multiple players with varied designations and offers multiple opportunities based on their scope of operations.

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Market Segmentation

•  Treatment Type Insights (Revenue, USD Bn, 2019 - 2031)
  • Mitral Valve Repair
    • Surgical Mitral Valve Repair
    • Transcatheter Mitral Valve Repair
  • Mitral Valve Replacement
    • Mechanical Valve Replacement
    • Biological Valve Replacement
    • Transcatheter Aortic Valve Replacement (TAVR)
  • Cardiac Resynchronization Therapy (CRT)
    • Biventricular Pacing
    • Implantable Cardioverter Defibrillators (ICDs)
  • Mitral Valve Therapeutics
    • Pharmacological Treatments
    • Device-Based Therapies
•  Indication Insights (Revenue, USD Bn, 2019 - 2031)
  • Mitral Valve Regurgitation
  • Mitral Valve Stenosis
  • Mitral Valve Prolapse
•  Device Type Insights (Revenue, USD Bn, 2019 - 2031)
  • Surgical Instruments
    • Heart-Lung Machines
    • Surgical Staplers
    • Sutures
  • Implant Devices
    • Mitral Valve Prostheses
    • Repair Devices (e.g., annuloplasty rings)
    • Diagnostic Devices
    • Echocardiograms
    • Cardiac Imaging Systems
•  End User Insights (Revenue, USD Bn, 2019 - 2031)
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Cardiac Rehabilitation Centers
  • Others
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
• Key Players Insights
  • Edwards Lifesciences Corporation
  • Medtronic Plc
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Corcym UK Limited
  • Artivion, Inc.
  • ShockWave Medical, Inc.
  • Valcare Medical
  • Braile Biomedica
  • Labcor Laboratorios Ltda
  • Zydus Lifesciences Limited
  • Affluent Medical
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Novartis AG